# Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

> **NCT01416038** · PHASE1 · COMPLETED · sponsor: **ImmunoVaccine Technologies, Inc. (IMV Inc.)** · enrollment: 19 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** DPX-Survivac
- **DRUG:** low dose cyclophosphamide (oral)

## Key facts

- **NCT ID:** NCT01416038
- **Lead sponsor:** ImmunoVaccine Technologies, Inc. (IMV Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416038, "Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01416038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*